Taking on Big Pharma-sized indications, tiny biotech claims early win in fat loss. Will it translate to diabetes, NASH and beyond?
As Big Pharma races to beef up their franchises in cardiometabolic diseases, a much smaller player wants to give them a run for their money,
And Rivus Pharmaceuticals, a tiny biotech with only seven full-time employees, says it has the preliminary data to suggest that its lead drug can play a big role in large indications like heart failure with preserved ejection fraction, type 2 diabetes and non-alcoholic steatohepatitis (NASH) — the last being a notorious wasteland for drug development efforts.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.